New perspectives on β-catenin control of cell fate and proliferation in colon cancer

Food and Chemical Toxicology

Volumn 74, Issue , 2014, Pages 14-19

  Yang, Yang ^a,b   Yang, Jing Jing ^a   Tao, Hui ^a   Jin, Wei Sen ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

Cancer stem cell; Colon cancer; Proliferation; Wnt; catenin

Indexed keywords

APC PROTEIN; BERBERINE; BETA CATENIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; WNT PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER STAGING; CELL FATE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLON CARCINOGENESIS; COLORECTAL CANCER; DISEASE MARKER; DRUG TARGETING; HUMAN; INTESTINE CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CELL TRANSFORMATION; COLON TUMOR; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BETA CATENIN; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; HUMANS; SIGNAL TRANSDUCTION;

EID: 84907615213     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2014.08.013     Document Type: Review

References (84)

1. Allen J.E., El-Deiry W.S. Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on beta-catenin. Oncotarget 2013, 4:184-191.
2. Alvin A., Miller K.I., Neilan B.A. Exploring the potential of endophytes from medicinal plants as sources of antimycobacterial compounds. Microbiol. Res 2014, 169:483-495.
3. Amado N.G., Fonseca B.F., Cerqueira D.M., Reis A.H., Simas A.B., Kuster R.M., et al. Effects of natural compounds on Xenopus embryogenesis: a potential read out for functional drug discovery targeting Wnt/beta-catenin signaling. Curr. Top. Med. Chem 2012, 12:2103-2113.
4. Arends M.J. Pathways of colorectal carcinogenesis. Appl. Immunohistochem. Mol. Morphol 2013, 21:97-102.
5. Astudillo P., Larrain J. Wnt signaling and cell-matrix adhesion. Curr. Mol. Med 2014, 14:209-220.
6. Berry W.L., Kim T.D., Janknecht R. Stimulation of beta-catenin and colon cancer cell growth by the KDM4B histone demethylase. Int. J. Oncol 2014, 44:1341-1348.
7. Bharati R., Jenkins M.A., Lindor N.M., Le Marchand L., Gallinger S., Haile R.W., et al. Does risk of endometrial cancer for women without a germline mutation in a DNA mismatch repair gene depend on family history of endometrial cancer or colorectal cancer?. Gynecol. Oncol 2014, 133:287-292.
8. Bin-Nun N., Lichtig H., Malyarova A., Levy M., Elias S., Frank D. PTK7 modulates Wnt signaling activity via LRP6. Development 2014, 141:410-421.
9. Caliceti C., Nigro P., Rizzo P., Ferrari R. ROS, Notch, and Wnt signaling pathways: crosstalk between three major regulators of cardiovascular biology. Biomed. Res. Int 2014, 2014:318714.
10. Cerella C., Sobolewski C., Dicato M., Diederich M. Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. Biochem. Pharmacol 2010, 80:1801-1815.
11. Chen J., Huang X.F. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol. Ther 2009, 8:1313-1317.
12. de Sousa E.M., Vermeulen L., Richel D., Medema J.P. Targeting Wnt signaling in colon cancer stem cells. Clin. Cancer Res 2011, 17:647-653.
13. Damaschke N.A., Yang B., Bhusari S., Svaren J.P., Jarrard D.F. Epigenetic susceptibility factors for prostate cancer with aging. Prostate 2013, 73:1721-1730.
14. Deng J., Lei W., Fu J.C., Zhang L., Li J.H., Xiong J.P. Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem. Biophys. Res. Commun 2014, 443:789-795.
15. DiRocco D.P., Kobayashi A., Taketo M.M., McMahon A.P., Humphreys B.D. Wnt4/beta-catenin signaling in medullary kidney myofibroblasts. J. Am. Soc. Nephrol 2013, 24:1399-1412.
16. Ellina M.I., Bouris P., Aletras A.J., Theocharis A.D., Kletsas D., Karamanos N.K. EGFR and HER2 exert distinct roles on colon cancer cell functional properties and expression of matrix macromolecules. Biochim. Biophys. Acta 2014, 1840:2651-2661.
17. Fanali C., Lucchetti D., Farina M., Corbi M., Cufino V., Cittadini A., et al. Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives. World J. Gastroenterol 2014, 20:923-942.
18. Findlay V.J., Wang C., Watson D.K., Camp E.R. Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther 2014, 21:181-187.
19. Fodde R., Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol 2007, 19:150-158.
20. Grady W.M., Pritchard C.C. Molecular alterations and biomarkers in colorectal cancer. Toxicol. Pathol 2014, 42:124-139.
21. Groulx J.F., Giroux V., Beausejour M., Boudjadi S., Basora N., Carrier J.C., et al. Integrin alpha6A splice variant regulates proliferation and the Wnt/beta-catenin pathway in human colorectal cancer cells. Carcinogenesis 2014, 35:1217-1227.
22. Grumolato L., Liu G., Mong P., Mudbhary R., Biswas R., Arroyave R., et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev 2010, 24:2517-2530.
23. Grynberg M., Teyssedre J., Andre C., Graesslin O. Rupture of ectopic pregnancy with negative serum beta-hCG leading to hemorrhagic shock. Obstet. Gynecol 2009, 113:537-539.
24. Guo D., Li Q., Lv Q., Wei Q., Cao S., Gu J. MiR-27a targets sFRP1 in hFOB cells to regulate proliferation, apoptosis and differentiation. PLoS ONE 2014, 9:e91354.
25. Hao H., Zhen Y., Wang Z., Chen F., Xie X. A novel therapeutic drug for colon cancer: EpCAM scFv-truncated protamine (tp)-siRNA. Cell Biol. Int 2013, 37:860-864.
26. Herbst A., Jurinovic V., Krebs S., Thieme S.E., Blum H., Goke B., et al. Comprehensive analysis of beta-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/beta-catenin signaling. BMC Genomics 2014, 15:74.
27. Huber S., Valente S., Chaimbault P., Schohn H. Evaluation of 2-pioglitazone, an analogue of pioglitazone, on colon cancer cell survival: evidence of drug treatment association with autophagy and activation of the Nrf2/Keap1 pathway. Int. J. Oncol 2014, 45:426-438.
28. Kanthan R., Senger J.L., Kanthan S.C. Molecular events in primary and metastatic colorectal carcinoma: a review. Patholog. Res. Int 2012, 2012:597497.
29. Keerthivasan S., Aghajani K., Dose M., Molinero L., Khan M.W., Venkateswaran V., et al. beta-Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells. Sci. Transl. Med 2014, 6:225ra228.
30. Kim J.H., Kim Y.H., Song G.Y., Kim D.E., Jeong Y.J., Liu K.H., et al. Ursolic acid and its natural derivative corosolic acid suppress the proliferation of APC-mutated colon cancer cells through promotion of beta-catenin degradation. Food Chem. Toxicol 2014, 67:87-95.
31. Li F.Y., Lai M.D. Colorectal cancer, one entity or three. J. Zhejiang Univ. Sci. B 2009, 10:219-229.
32. Li H., Lee H.J., Ahn Y.H., Kwon H.J., Jang C.Y., Kim W.Y., et al. Tussilagone suppresses colon cancer cell proliferation by promoting the degradation of beta-catenin. Biochem. Biophys. Res. Commun 2014, 443:132-137.
33. Li N., Xi Y., Tinsley H.N., Gurpinar E., Gary B.D., Zhu B., et al. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/beta-catenin signaling. Mol. Cancer Ther 2013, 12:1848-1859.
34. Li R., Grimm S.A., Chrysovergis K., Kosak J., Wang X., Du Y., et al. Obesity, rather than diet, drives epigenomic alterations in colonic epithelium resembling cancer progression. Cell Metab 2014, 19:702-711.
35. Limongelli V., Bonomi M., Marinelli L., Gervasio F.L., Cavalli A., Novellino E., et al. Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition. Proc. Natl Acad. Sci. U.S.A. 2010, 107:5411-5416.
36. Liu Y.Z., Wu K., Huang J., Liu Y., Wang X., Meng Z.J., et al. The PTEN/PI3K/Akt and Wnt/beta-catenin signaling pathways are involved in the inhibitory effect of resveratrol on human colon cancer cell proliferation. Int. J. Oncol 2014, 45:104-112.
37. Luo Y., Wong C.J., Kaz A.M., Dzieciatkowski S., Carter K.T., Morris S.M., et al. Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology 2014, 147:418-429. e8.
38. Manna S.K., Tanaka N., Krausz K.W., Haznadar M., Xue X., Matsubara T., et al. Biomarkers of coordinate metabolic reprogramming in colorectal tumors in mice and humans. Gastroenterology 2014, 146:1313-1324.
39. Masuko K., Okazaki S., Satoh M., Tanaka G., Ikeda T., Torii R., et al. Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells. PLoS ONE 2012, 7:e29728.
40. Mathonnet M., Perraud A., Christou N., Akil H., Melin C., Battu S., et al. Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells. World J. Gastroenterol 2014, 20:4189-4196.
41. Metcalfe C., Ibrahim A.E., Graeb M., de la Roche M., Schwarz-Romond T., Fiedler M., et al. Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer. Cancer Res 2010, 70:6629-6638.
42. Moon B.S., Jeong W.J., Park J., Kim T.I., Min do S., Choi K.Y. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/beta-catenin signaling. J. Natl Cancer Inst 2014, 106:djt373.
43. Morales C., Rachidi S., Hong F., Sun S., Ouyang X., Wallace C., et al. Immune chaperone gp96 drives the contributions of macrophages to inflammatory colon tumorigenesis. Cancer Res 2014, 74:446-459.
44. Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res 2014, 74:3238-3247.
45. Muhidin S.O., Magan A.A., Osman K.A., Syed S., Ahmed M.H. The relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome. J. Obes 2012, 2012:637538.
46. Nishiya N., Oku Y., Kumagai Y., Sato Y., Yamaguchi E., Sasaki A., et al. A zebrafish chemical suppressor screening identifies small molecule inhibitors of the Wnt/beta-catenin pathway. Chem. Biol 2014, 21:530-540.
47. Pais R., Silaghi H., Silaghi A.C., Rusu M.L., Dumitrascu D.L. Metabolic syndrome and risk of subsequent colorectal cancer. World J. Gastroenterol 2009, 15:5141-5148.
48. Paul I., Bhattacharya S., Chatterjee A., Ghosh M.K. Current understanding on EGFR and Wnt/beta-catenin signaling in glioma and their possible crosstalk. Genes Cancer 2013, 4:427-446.
49. Pendas-Franco N., Aguilera O., Pereira F., Gonzalez-Sancho J.M., Munoz A. Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. Anticancer Res 2008, 28:2613-2623.
50. Piazzi G., D'Argenio G., Prossomariti A., Lembo V., Mazzone G., Candela M., et al. Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota. Int. J. Cancer 2014, 135:2004-2013.
51. Puglisi M.A., Tesori V., Lattanzi W., Gasbarrini G.B., Gasbarrini A. Colon cancer stem cells: controversies and perspectives. World J. Gastroenterol 2013, 19:2997-3006.
52. Rahmani M., Carthy J.M., McManus B.M. Mapping of the Wnt/beta-catenin/TCF response elements in the human versican promoter. Methods Mol. Biol 2012, 836:35-52.
53. Ramirez A., Boulaiz H., Morata-Tarifa C., Peran M., Jimenez G., Picon-Ruiz M., et al. HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound. Oncotarget 2014, 5:3590-3606.
54. Ring L., Neth P., Weber C., Steffens S., Faussner A. beta-Catenin-dependent pathway activation by both promiscuous "canonical" WNT3a-, and specific "noncanonical" WNT4- and WNT5a-FZD receptor combinations with strong differences in LRP5 and LRP6 dependency. Cell. Signal 2014, 26:260-267.
55. Riondino S., Roselli M., Palmirotta R., Della-Morte D., Ferroni P., Guadagni F. Obesity and colorectal cancer: role of adipokines in tumor initiation and progression. World J. Gastroenterol 2014, 20:5177-5190.
56. Robertson J.K., Danzmann K., Charles S., Blake K., Olivares A., Bamikole S., et al. Targeting the Wnt pathway in zebrafish as a screening method to identify novel therapeutic compounds. Exp. Biol. Med. (Maywood) 2014, 239:169-176.
57. Savas S., Younghusband H.B. dbCPCO: a database of genetic markers tested for their predictive and prognostic value in colorectal cancer. Hum. Mutat 2010, 31:901-907.
58. Schon S., Flierman I., Ofner A., Stahringer A., Holdt L., Kolligs F.T., et al. beta-catenin regulates NF-kappaB activity via TNFRSF19 in colorectal cancer cells. Int. J. Cancer 2014, 135:1800-1811.
59. Selgrad M., Bornschein J., Kandulski A., Hille C., Weigt J., Roessner A., et al. Helicobacter pylori but not gastrin is associated with the development of colonic neoplasms. Int. J. Cancer 2014, 135:1127-1131.
60. Shackleford G., Makoukji J., Grenier J., Liere P., Meffre D., Massaad C. Differential regulation of Wnt/beta-catenin signaling by Liver X Receptors in Schwann cells and oligodendrocytes. Biochem. Pharmacol 2013, 86:106-114.
61. Shenoy A.K., Fisher R.C., Butterworth E.A., Pi L., Chang L.J., Appelman H.D., et al. Transition from colitis to cancer: high Wnt activity sustains the tumor-initiating potential of colon cancer stem cell precursors. Cancer Res 2012, 72:5091-5100.
62. Sirnes S., Bruun J., Kolberg M., Kjenseth A., Lind G.E., Svindland A., et al. Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. Int. J. Cancer 2012, 131:570-581.
63. Sirnes S., Lind G.E., Bruun J., Fykerud T.A., Mesnil M., Lothe R.A., et al. Connexins in colorectal cancer pathogenesis. Int. J. Cancer 2014, 10.1002/ijc.28911.
64. Tai W.P., Hu P.J., Wu J., Lin X.C. The inhibition of Wnt/beta-catenin signaling pathway in human colon cancer cells by sulindac. Tumori 2014, 100:97-101.
65. Tanneberger K., Pfister A.S., Brauburger K., Schneikert J., Hadjihannas M.V., Kriz V., et al. Amer1/WTX couples Wnt-induced formation of PtdIns(4,5)P2 to LRP6 phosphorylation. EMBO J. 2011, 30:1433-1443.
66. To S.K., Zeng W.J., Zeng J.Z., Wong A.S. Hypoxia triggers a Nur77-beta-catenin feed-forward loop to promote the invasive growth of colon cancer cells. Br. J. Cancer 2014, 110:935-945.
67. Torres S., Bartolome R.A., Mendes M., Barderas R., Fernandez-Acenero M.J., Pelaez-Garcia A., et al. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin. Cancer Res 2013, 19:6006-6019.
68. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011, 71:1263-1271.
69. Tsai M.L., Chiou Y.S., Chiou L.Y., Ho C.T., Pan M.H. Garcinol suppresses inflammation-associated colon carcinogenesis in mice. Mol. Nutr. Food Res 2014, 10.1002/mnfr.201400149.
70. Vaiopoulos A.G., Athanasoula K.C., Papavassiliou A.G. Epigenetic modifications in colorectal cancer: molecular insights and therapeutic challenges. Biochim. Biophys. Acta 2014, 1842:971-980.
71. Vargas T., Moreno-Rubio J., Herranz J., Cejas P., Molina S., Gonzalez-Vallinas M., et al. Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer. Mol. Oncol 2014, 10.1016/j.molonc.2014.05.015.
72. Vinyoles M., Del Valle-Perez B., Curto J., Vinas-Castells R., Alba-Castellon L., Garcia de Herreros A., et al. Multivesicular GSK3 sequestration upon Wnt signaling is controlled by p120-catenin/cadherin interaction with LRP5/6. Mol. Cell 2014, 53:444-457.
73. Walker A.S., Johnson E.K., Maykel J.A., Stojadinovic A., Nissan A., Brucher B., et al. Future directions for the early detection of colorectal cancer recurrence. J. Cancer 2014, 5:272-280.
74. Walther A., Johnstone E., Swanton C., Midgley R., Tomlinson I., Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat. Rev. Cancer 2009, 9:489-499.
75. Wang D., Fu L., Ning W., Guo L., Sun X., Dey S.K., et al. Peroxisome proliferator-activated receptor delta promotes colonic inflammation and tumor growth. Proc. Natl Acad. Sci. U.S.A. 2014, 111:7084-7089.
76. Wang S., Bao Z., Liang Q.M., Long J.W., Xiao Z.S., Jiang Z.J., et al. Octreotide stimulates somatostatin receptor-induced apoptosis of SW480 colon cancer cells by activation of glycogen synthase kinase-3beta, a Wnt/beta-catenin pathway modulator. Hepatogastroenterology 2013, 60:1639-1646.
77. Watanabe K., Biesinger J., Salmans M.L., Roberts B.S., Arthur W.T., Cleary M., et al. Integrative ChIP-seq/microarray analysis identifies a CTNNB1 target signature enriched in intestinal stem cells and colon cancer. PLoS ONE 2014, 9:e92317.
78. Wu R., Hu T.C., Rehemtulla A., Fearon E.R., Cho K.R. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin. Cancer Res 2011, 17:7359-7372.
79. Xing J., Cao G., Fu C. HMGA1 interacts with beta-catenin to positively regulate Wnt/beta-catenin signaling in colorectal cancer cells. Pathol. Oncol. Res 2014.
80. Yagishita H., Yoshida T., Ishiguro K., Numata Y., Okayasu I. Epithelial and stromal genetic instability linked to tumor suppressor genes in ulcerative colitis-associated tumorigenesis. Scand. J. Gastroenterol 2008, 43:559-566.
81. Yee J., Kim D.H., Rosen M.P., Lalani T., Carucci L.R., Cash B.D., et al. ACR appropriateness criteria colorectal cancer screening. J. Am. Coll. Radiol 2014, 11:543-551.
82. Zeineldin M., Miller M.A., Sullivan R., Neufeld K.L. Nuclear adenomatous polyposis coli suppresses colitis-associated tumorigenesis in mice. Carcinogenesis 2014, 35:1881-1890.
83. Zhang J., Cao H., Zhang B., Xu X., Ruan H., Yi T., et al. Berberine potently attenuates intestinal polyps growth in ApcMin mice and familial adenomatous polyposis patients through inhibition of Wnt signalling. J. Cell. Mol. Med 2013, 17:1484-1493.
84. Zheng P., Liu Y.X., Chen L., Liu X.H., Xiao Z.Q., Zhao L., et al. Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J. Proteome Res 2010, 9:4897-4905.